Table 1.
Changes in final body mass index, waist circumference, plasma insulin (μIU/mL) level, and HOMA‐B in the different studied groups
| Control group (I) | Untreated | l‐Carnitine‐treated | |||
|---|---|---|---|---|---|
| Hyperuricemic group (II) | Hyperuricemic Fructose‐supplemented group (III) | Hyperuricemic group (IV) | Hyperuricemic Fructose‐supplemented group (V) | ||
| Final body mass index | 0.491 ± 0.014 | 0.489 ± 0.007 | 0.550a, b ± 0.007 | 0.569a, b ± 0.008 | 0.518b, c, d ± 0.01 |
| Waist Circumference (cm) | 12.85 ± 0.2 | 13.25 ± 0.13 | 14.2a, b ± 0.17 | 14.2a, b ± 0.17 | 13.5a, c, d ± 0.15 |
| Plasma Insulin Level (μIU/ml) | 4.55 ± 0.08 | 4.7 ± 0.07 | 4.77 ± 0.08 | 4.57 ± 0.09 | 4.68 ± 0.08 |
| HOMA‐B | 17,000 ± 1,194 | 4,026.53a ± 196.7 | 2,895a ± 83.84 | 6,136.75a ± 535.91 | 3,619.05a ± 197.02 |
Number of rats in each group is 10 rats.
a
Significance by LSD at p < .05 compared to control group (I).
b
Significance by LSD at p < .05 compared to untreated hyperuricemic group (II).
c
Significance by LSD at p < .05 compared to untreated hyperuricemic fructose‐supplemented group (III).
d
Significance by LSD at p < .05 compared to l‐Carnitine‐treated hyperuricemic group (IV).